Pharmacy Times®
Specialty Pharmacy Times
  • Top 10 Trends in Specialty Pharmacy
  • The Specialty Pharmacy’s Role in Ensuring the Effectiveness of New Hepatitis C Drugs
  • Co-pay Coupons Are No Bargain for Specialty Pharmacies
  • Specialty Pipeline Highlights
  • Newly Approved Oncology Agents
  • Generic Drug Labeling Issues: How They Could Affect Biosimilars
Added Benefit for Hepatitis C Treatment Not Proven
Davy James, Associate Editor
Data for daclatasvir not suitable to prove added benefit.
Prime Therapeutics Specialty Pharmacy Achieves 95 Percent Member Satisfaction
Related study shows satisfied specialty pharmacy members more likely to be adherent to their biologic anti-inflammatory medicines.
Pharmacists Rank High on Honesty, Ethics in Gallup Poll
Meghan Ross, Associate Editor
A total of 65% of patients polled rate pharmacists as having very high or high standards of ethics and honesty.
Perjeta by Genentech, Inc
Perjeta (pertuzumab) is now approved for the neoadjuvant treatment of breast cancer.
Cyramza by Eli Lilly
Michael R. Page, PharmD, RPh
Cyramza (ramucirumab) was approved for treatment of patients with advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma after disease progression.
Featured Video
Ongoing Challenges for Specialty Pharmacy
Thomas Morrow, MD, chief medical officer at Next IT, discusses hurdles that specialty pharmacies need to overcome.
Industry Guide
We've created this Industry Guide with close to 300 companies and organizations as a one-stop guide for industry stakeholders in the specialty pharmacy space.
Current Issue
Conference Calendar
â—„        December 2014        â–º
Featured Company Profile
Pharmacy Times
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright Pharmacy Times 2006-2013
Intellisphere, LLC. All Rights Reserved.